MedPath

Investigation of imaging and neuropsychological biomarkers for aggressive behavior during therapy with the anticonvulsants levetiracetam and perampanel.

Conditions
G40
Epilepsy
Registration Number
DRKS00030739
Lead Sponsor
niversitätsklinikum der RWTH Aachen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
140
Inclusion Criteria

Patients with a confirmed diagnosis of epilepsy aged 18-70 years. Furthermore, age-matched controls without neurological or other severe diseases should be recruited.

Exclusion Criteria

Participants are excluded if they are not admissible to MRI.

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in neuropsychological and brain functional characteristics of patients during treatment and after discontinuation of levetiracetam and perampanel, respectively. (FMRI, OASM, BDI, BIS, ASQ, EpiTrack, BPAQ, SCID-V)
Secondary Outcome Measures
NameTimeMethod
Tolerability of side effects
© Copyright 2025. All Rights Reserved by MedPath